Medthority’s Post

Hear from our CEO, Rohan Palekar about his perspective on what it will take to reverse fibrosis in patients with advanced metabolic dysfunction-associated steatohepatitis (MASH) in his recent Endpoints News article. Rohan also shares the latest developments in potential treatment options, including our lead treatment candidate for MASH now in Phase 3 clinical trials. Read the full article here: https://lnkd.in/g8V_Gbwy #Innovation #MASH #LiverDisease 

New data to help in treatment decisions for Crohn's disease patients! A study recently published in the New England Journal of Medicine shows that risankizumab, brand name SKYRIZI® is more effective than ustekinumab, brand name STELARA® in achieving clinical and endoscopic remission in patients with moderate-to-severe Crohn’s disease who had unacceptable side effects with anti-TNF therapy or an inadequate response to such therapy. Significant strides in treatment options! Find the clinical evidence for both #SKYRIZI & #STELARA on DRUGDOCS® Read the paper here: https://lnkd.in/ex5znVzp #CrohnsDisease #MedicalResearch #IBD

What would you do if your first line treatment fails in your patient with Takayasu? Dr Raju Khubchandani and Prof. Michaël Hofer talk about the possibility to use Tocilizumab and also exchange about the lack of prospective randomized controlled trials in childrens. Get the full discussion in the JIR Academy Forum https://lnkd.in/e3cN5cdR

📝 A new study published in RMD Open established that guselkumab improved efficacy and patient-reported outcomes in patients with PsA and TNFi-IR. More news: psoriasis-hub.com #PsoriaticArthritis #MedNews #MedEd

In this cohort study with up to 5 years of follow-up, dupilumab maintained its clinical effectiveness, while two-thirds of patients tapered to a dosing interval of every 3 or 4 weeks. https://ja.ma/3yCtPRu

Uncover insights into #DAPT duration post-flow diverter treatment. Dr. Jildaz CAROFF shares findings from an analysis involving 700 patients, revealing peaks in DAPT length and excellent safety outcomes. Optimize therapeutic strategies based on real-world evidence! https://ow.ly/ozHh50QCLT8

Clinical trials rely on accurate, high-quality assessments to drive drug development success. Discover how blinded independent central reviews (BICRs) for imaging eligibility and disease progression are crucial for achieving this. Download our whitepaper to learn more: https://lnkd.in/enr9ZYNd #ClinicalTrials #BICR #MedicalImaging

Today, we announced positive interim data from our ongoing Phase 2 trial evaluating the safety and efficacy of our product candidate in people with #ChronicNeutropenia (CN). We also announced that we’ve started screening patients for enrollment into our pivotal Phase 3 trial, the 4WARD study, to evaluate our product candidate in people with congenital, acquired primary autoimmune, or idiopathic CN.   We’re hosting a webinar today at 8:00 am ET and will detail the interim results, feature clinical experts in the treatment of CN, and discuss the 4WARD study.   Learn more here: https://lnkd.in/eaDtEtT6 #Progress4Patients 

𝐏𝐮𝐫𝐞𝐓𝐞𝐜𝐡 𝐀𝐝𝐯𝐚𝐧𝐜𝐞𝐬 𝐈𝐏𝐅 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐰𝐢𝐭𝐡 𝐋𝐘𝐓-𝟏𝟎𝟎 𝐚𝐭 𝐂𝐇𝐄𝐒𝐓 𝟐𝟎𝟐𝟒 PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) PureTech Health, a clinical-stage biotherapeutics company, recently presented two oral presentations and a poster at the CHEST 2024 Annual Meeting in Boston, focusing on LYT-100 (deupirfenidone) for idiopathic pulmonary fibrosis (IPF). The presentations highlighted significant gaps in disease management and quality of life for IPF patients. A survey of 90 participants revealed that common symptoms such as shortness of breath, fatigue, and cough significantly interfere with daily activities, underscoring the need for better treatments. Additionally, the company shared insights into its ongoing Phase 2b ELEVATE IPF trial, which is evaluating the efficacy and safety of LYT-100. By utilizing a Bayesian approach, the trial enhances statistical power by incorporating historical placebo data, reducing the number of patients treated with placebo. The results from this trial are expected by the end of 2024 and could serve as the foundation for advancing LYT-100 into Phase 3 and eventual global registration, pending positive outcomes. #IPF #PulmonaryFibrosis #Biopharma #ClinicalResearch #BayesianAnalysis #CHEST2024 #HealthcareInnovation

https://lnkd.in/dKyaF6pc "Redefining diagnostics through a transformative labeling framework that champions competency-based decision-making, integrates compassionomics, and prioritizes patient and family-centered care to achieve unparalleled diagnostic and therapeutic excellence."